Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer

Stephanie I. Hines, L. A. Vallow, Winston Tan, R. B. McNeil, E. A. Perez, A. Jain

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Women with triple-negative (TN) breast cancer are at increased risk of distant metastases and have reduced survival versus other breast cancer patients. Relative survival of women with TN breast cancer who develop brain metastases is unknown. Methods: Patients with breast cancer who developed brain metastases at our institution from 1993 to 2006 were reviewed. Four survival time intervals were compared in patients with TN disease and those with non-TN disease: initial diagnosis to distant metastases, distant metastases to brain metastases, brain metastases to death, and overall diagnosis to death. Results: One hundred and eighteen patients were identified. Fifty-one (50%) of 103 were estrogen receptor positive, 26 (39%) of 67 were human epidermal growth factor receptor 2 positive, and 20 (22%) of 91 were TN. Survival times were shorter for TN patients, with overall survival of 26 months in TN patients versus 49 months for non-TN patients. In TN patients, time to development of distant metastases, brain metastases, and death after brain metastases was shorter than in non-TN patients. Conclusion: Patients with TN disease were more likely to develop distant metastases earlier than non-TN patients, developed brain metastases sooner, and had shorter overall survival.

Original languageEnglish (US)
Pages (from-to)1561-1565
Number of pages5
JournalAnnals of Oncology
Volume19
Issue number9
DOIs
StatePublished - 2008

Fingerprint

Triple Negative Breast Neoplasms
Estrogens
Neoplasm Metastasis
Brain
Survival
human ERBB2 protein
Breast Neoplasms
Brain Death
Estrogen Receptors

Keywords

  • Brain metastasis
  • Brain tumors
  • Breast cancer
  • Hormonal therapy
  • Survival
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. / Hines, Stephanie I.; Vallow, L. A.; Tan, Winston; McNeil, R. B.; Perez, E. A.; Jain, A.

In: Annals of Oncology, Vol. 19, No. 9, 2008, p. 1561-1565.

Research output: Contribution to journalArticle

@article{e29b8695996245cd925ccd2f840ebcda,
title = "Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer",
abstract = "Background: Women with triple-negative (TN) breast cancer are at increased risk of distant metastases and have reduced survival versus other breast cancer patients. Relative survival of women with TN breast cancer who develop brain metastases is unknown. Methods: Patients with breast cancer who developed brain metastases at our institution from 1993 to 2006 were reviewed. Four survival time intervals were compared in patients with TN disease and those with non-TN disease: initial diagnosis to distant metastases, distant metastases to brain metastases, brain metastases to death, and overall diagnosis to death. Results: One hundred and eighteen patients were identified. Fifty-one (50{\%}) of 103 were estrogen receptor positive, 26 (39{\%}) of 67 were human epidermal growth factor receptor 2 positive, and 20 (22{\%}) of 91 were TN. Survival times were shorter for TN patients, with overall survival of 26 months in TN patients versus 49 months for non-TN patients. In TN patients, time to development of distant metastases, brain metastases, and death after brain metastases was shorter than in non-TN patients. Conclusion: Patients with TN disease were more likely to develop distant metastases earlier than non-TN patients, developed brain metastases sooner, and had shorter overall survival.",
keywords = "Brain metastasis, Brain tumors, Breast cancer, Hormonal therapy, Survival, Triple-negative breast cancer",
author = "Hines, {Stephanie I.} and Vallow, {L. A.} and Winston Tan and McNeil, {R. B.} and Perez, {E. A.} and A. Jain",
year = "2008",
doi = "10.1093/annonc/mdn283",
language = "English (US)",
volume = "19",
pages = "1561--1565",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer

AU - Hines, Stephanie I.

AU - Vallow, L. A.

AU - Tan, Winston

AU - McNeil, R. B.

AU - Perez, E. A.

AU - Jain, A.

PY - 2008

Y1 - 2008

N2 - Background: Women with triple-negative (TN) breast cancer are at increased risk of distant metastases and have reduced survival versus other breast cancer patients. Relative survival of women with TN breast cancer who develop brain metastases is unknown. Methods: Patients with breast cancer who developed brain metastases at our institution from 1993 to 2006 were reviewed. Four survival time intervals were compared in patients with TN disease and those with non-TN disease: initial diagnosis to distant metastases, distant metastases to brain metastases, brain metastases to death, and overall diagnosis to death. Results: One hundred and eighteen patients were identified. Fifty-one (50%) of 103 were estrogen receptor positive, 26 (39%) of 67 were human epidermal growth factor receptor 2 positive, and 20 (22%) of 91 were TN. Survival times were shorter for TN patients, with overall survival of 26 months in TN patients versus 49 months for non-TN patients. In TN patients, time to development of distant metastases, brain metastases, and death after brain metastases was shorter than in non-TN patients. Conclusion: Patients with TN disease were more likely to develop distant metastases earlier than non-TN patients, developed brain metastases sooner, and had shorter overall survival.

AB - Background: Women with triple-negative (TN) breast cancer are at increased risk of distant metastases and have reduced survival versus other breast cancer patients. Relative survival of women with TN breast cancer who develop brain metastases is unknown. Methods: Patients with breast cancer who developed brain metastases at our institution from 1993 to 2006 were reviewed. Four survival time intervals were compared in patients with TN disease and those with non-TN disease: initial diagnosis to distant metastases, distant metastases to brain metastases, brain metastases to death, and overall diagnosis to death. Results: One hundred and eighteen patients were identified. Fifty-one (50%) of 103 were estrogen receptor positive, 26 (39%) of 67 were human epidermal growth factor receptor 2 positive, and 20 (22%) of 91 were TN. Survival times were shorter for TN patients, with overall survival of 26 months in TN patients versus 49 months for non-TN patients. In TN patients, time to development of distant metastases, brain metastases, and death after brain metastases was shorter than in non-TN patients. Conclusion: Patients with TN disease were more likely to develop distant metastases earlier than non-TN patients, developed brain metastases sooner, and had shorter overall survival.

KW - Brain metastasis

KW - Brain tumors

KW - Breast cancer

KW - Hormonal therapy

KW - Survival

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=50849089897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849089897&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn283

DO - 10.1093/annonc/mdn283

M3 - Article

C2 - 18534964

AN - SCOPUS:50849089897

VL - 19

SP - 1561

EP - 1565

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -